Bevacizumab/interferon-α
1
Reactions 1461, p11 - 20 Jul 2013 S Bevacizumab/interferon-α Cognitive impairment and personality disorders in an elderly patient: case report A 71-year-old woman developed cognitive impairment and personality disorders during treatment with bevacizumab and interferon-α for metastatic renal cancer. The woman received bevacizumab and interferon-α [dosages and routes not stated] from 2005 to 2009. During anti-angiogenic therapy, she developed psychiatric symptoms such as social withdrawal, emotional coldness, paranoid personality disorders, dementia and memory impairment [duration of treatment to onset of reactions not stated]. Due to cardiac toxicity, the anti-angiogenic treatment was withdrawn. Imaging studies of the head did not show structural damages or brain lesions. Pharmacotherapy and psychotherapy were suggested [outcome not stated]. New metastases were seen in 2010, and the woman started receiving everolimus. Her everolimus dose was reduced due to grade 3 haematological toxicity. Author comment: "Cognitive changes and dysfunction after common cancer chemotherapy and recently appearing after biologic agents are increasing as a disturbing side-effect in cancer survivors." Wachula E, et al. Personality disorders as a result of symptom of chemotherapy- related cognitive impairment (CRCI) antiangiogenic treatment for metastatic renal cancer: A case report of 71-year-old women. Journal of Clinical Oncology 31 (Suppl. 1): abstr. e13560, No. 15, 20 May 2013 [abstract] - Poland 803090217 1 Reactions 20 Jul 2013 No. 1461 0114-9954/13/1461-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Bevacizumab/interferon-α
Reactions 1461, p11 - 20 Jul 2013
SBevacizumab/interferon-αCognitive impairment and personality disorders inan elderly patient: case report
A 71-year-old woman developed cognitive impairment andpersonality disorders during treatment with bevacizumab andinterferon-α for metastatic renal cancer.
The woman received bevacizumab and interferon-α[dosages and routes not stated] from 2005 to 2009. Duringanti-angiogenic therapy, she developed psychiatric symptomssuch as social withdrawal, emotional coldness, paranoidpersonality disorders, dementia and memory impairment[duration of treatment to onset of reactions not stated]. Due tocardiac toxicity, the anti-angiogenic treatment was withdrawn.
Imaging studies of the head did not show structuraldamages or brain lesions. Pharmacotherapy andpsychotherapy were suggested [outcome not stated]. Newmetastases were seen in 2010, and the woman startedreceiving everolimus. Her everolimus dose was reduced dueto grade 3 haematological toxicity.
Author comment: "Cognitive changes and dysfunctionafter common cancer chemotherapy and recently appearingafter biologic agents are increasing as a disturbing side-effectin cancer survivors."Wachula E, et al. Personality disorders as a result of symptom of chemotherapy-related cognitive impairment (CRCI) antiangiogenic treatment for metastatic renalcancer: A case report of 71-year-old women. Journal of Clinical Oncology 31(Suppl. 1): abstr. e13560, No. 15, 20 May 2013 [abstract] - Poland 803090217
1
Reactions 20 Jul 2013 No. 14610114-9954/13/1461-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
